{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:47:51Z","timestamp":1756385271274},"reference-count":26,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2019.1852","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T14:50:24Z","timestamp":1557154224000},"source":"Crossref","is-referenced-by-count":3,"title":["Importance of the correct assessment of bone fractures in the clinical management of metastatic castration\u2011resistant prostate cancer treated with radium\u2011223: A case report"],"prefix":"10.3892","author":[{"given":"Elisa","family":"Lodi Rizzini","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, S. Orsola\u2011Malpighi Hospital, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ghedini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, S. Orsola\u2011Malpighi Hospital, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Cardano","sequence":"additional","affiliation":[{"name":"DIMES University of Bologna, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bellarosa","sequence":"additional","affiliation":[{"name":"DIMES University of Bologna, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Morganti","sequence":"additional","affiliation":[{"name":"DIMES University of Bologna, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, S. Orsola\u2011Malpighi Hospital, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Monari","sequence":"additional","affiliation":[{"name":"Radiation Oncology Center, S. Orsola\u2011Malpighi Hospital, I\u201140138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"key20200713202434_b1-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200713202434_b2-mco-0-0-1852","article-title":"Zytiga (abiraterone acetate) Summary of product characteristics","author":"European Medicines"},{"key":"key20200713202434_b3-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"key20200713202434_b4-mco-0-0-1852","first-page":"258","article-title":"Preventive management of bone disease in advanced prostate cancer","volume":"71","author":"Rosino-S\u00e1nchez","year":"2018","journal-title":"Arch Esp Urol"},{"key":"key20200713202434_b5-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1020840311573","article-title":"Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer","volume":"21","author":"Smith","year":"2002","journal-title":"Cancer Metastasis Rev"},{"key":"key20200713202434_b6-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma","volume":"97","author":"Smith","year":"2003","journal-title":"Cancer"},{"key":"key20200713202434_b7-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cncr.20766","article-title":"Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy","volume":"103","author":"Tanvetyanon","year":"2005","journal-title":"Cancer"},{"key":"key20200713202434_b8-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"key20200713202434_b9-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"key":"key20200713202434_b10-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jfma.2017.04.005","article-title":"Optimal usage of radium-223 in metastatic castration-resistant prostate cancer","volume":"116","author":"Cha","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"key20200713202434_b11-mco-0-0-1852","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"key20200713202434_b12-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bju.14015","article-title":"Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: Men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures","volume":"121","author":"Poon","year":"2018","journal-title":"BJU Int"},{"key":"key20200713202434_b13-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"S5023","DOI":"10.1200\/JCO.2017.35.15_suppl.5023","article-title":"Impact of timing of administration of bone supportive therapy on pain palliation from radium-223","volume":"35","author":"Yap","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20200713202434_b14-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: An international, early access, open-label, single-arm phase 3b trial","volume":"17","author":"Saad","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20200713202434_b15-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2018.04.014","article-title":"The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer","volume":"68","author":"Saad","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"key20200713202434_b16-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"key20200713202434_b17-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4103\/1008-682X.122591","article-title":"Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer","volume":"16","author":"Saylor","year":"2014","journal-title":"Asian J Androl"},{"key":"key20200713202434_b18-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ucl.2012.07.009","article-title":"Bone-targeted agents: Preventing skeletal complications in prostate cancer","volume":"39","author":"Morgans","year":"2012","journal-title":"Uro Clin North Am"},{"key":"key20200713202434_b19-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1210\/jc.84.10.3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200713202434_b20-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.prnil.2017.02.003","article-title":"68Ga-prostate-specific membrane antigen-positron emission tomography\/computed tomography in advanced prostate cancer: Current state and future trends","volume":"5","author":"Udovicich","year":"2017","journal-title":"Prostate Int"},{"key":"key20200713202434_b21-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: A systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"key":"key20200713202434_b22-mco-0-0-1852","first-page":"254","article-title":"Role of diffusion WIs and T2 * GRE pulse sequences in dubious vertebral marrow pathological lesions","volume":"19","author":"Osman","year":"2007","journal-title":"J Egypt Natl Canc Inst"},{"key":"key20200713202434_b23-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1007\/s12306-013-0277-9","article-title":"Atraumatic vertebral compression fractures: Differential diagnosis between benign osteoporotic and malignant fractures by MRI","volume":"97","author":"Cicala","year":"2013","journal-title":"Musculoskelet Surg"},{"key":"key20200713202434_b24-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ctrv.2017.09.008","article-title":"Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer","volume":"61","author":"Brodowicz","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"key20200713202434_b25-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"key20200713202434_b26-mco-0-0-1852","doi-asserted-by":"publisher","first-page":"2568031","DOI":"10.1155\/2016\/2568031","article-title":"Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: An update on literature with case presentation","volume":"2016","author":"Nguyen","year":"2016","journal-title":"Int J Mol Imaging"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:24:42Z","timestamp":1594668282000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2019.1852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.3892\/mco.2019.1852","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]}}}